These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 17859150)

  • 1. The Effects of Priscol (2 Benzyl-4, 5 Imidazoline HCl) on Peripheral Vascular Diseases, Hypertension and Circulation in Patients.
    Grimson KS; Reardon MJ; Marzoni FA; Hendrix JP
    Ann Surg; 1948 May; 127(5):968-90. PubMed ID: 17859150
    [No Abstract]   [Full Text] [Related]  

  • 2. The effects of priscol (2-benzyl-4,5-imidazoline HCl) on peripheral vascular diseases, hypertension and circulation in patients.
    GRIMSON KS; REARDON MJ
    Trans South Surg Assoc; 1947-1948; 59 (1 vol.)():229-52. PubMed ID: 18105752
    [No Abstract]   [Full Text] [Related]  

  • 3. The effects of priscol (2-benzyl-4,5-imidazoline hydrochloride) in the treatment of peripheral vascular diseases.
    FRANK N; STRAZZA JA; HELSPER JT
    Ann Intern Med; 1951 Jul; 35(1):19-38. PubMed ID: 14847446
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical and experimental study of the effect of 2-benzyl-4-5-imidazoline (priscol) in secondary shock].
    PENA Y DE LA PENA E; GARCIA RAMOS J; GARCIA CARRIZOSA R; VARGAS ELIAS VM
    Bol Sanid Mil; 1953 Jul; 6(7):195-208. PubMed ID: 13105792
    [No Abstract]   [Full Text] [Related]  

  • 5. Toxicological and pharmacological data concerning 2-benzyl-imidazoline hydrochloride (priscol).
    BARRETT W; CAMERON A
    Fed Proc; 1948 Mar; 7(1 Pt 1):205. PubMed ID: 18857923
    [No Abstract]   [Full Text] [Related]  

  • 6. [Benzyl imidazoline in the treatment of peripheral circulatory diseases].
    DI CIO AV; KLEIN L
    Prensa Med Argent; 1953 Aug; 40(35):2302-6. PubMed ID: 13112016
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
    Ohno O; Ye M; Koyama T; Yazawa K; Mura E; Matsumoto H; Ichino T; Yamada K; Nakamura K; Ohno T; Yamaguchi K; Ishida J; Fukamizu A; Uemura D
    Bioorg Med Chem; 2008 Aug; 16(16):7843-52. PubMed ID: 18672373
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The usefulness of benzyl-inidazoline hydrochloride (Priscol) in cerebral affections consecutive to circulatory deficits].
    ROCH M; ROCH-BESSER B
    Schweiz Med Wochenschr; 1947 Jun; 77(25-26):679. PubMed ID: 20252307
    [No Abstract]   [Full Text] [Related]  

  • 9. Biphasic dose-dependent modulation of cardiac parasympathetic activity by moxonidine, an imidazoline I1-receptor agonist.
    Turcani M
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):524-35. PubMed ID: 19034032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interruption of central neuronal pathway of imidazoline I1 receptor mediates the hypertensive effect of cyclosporine in rats.
    El-Mas MM; Omar AG; Helmy MM; Mohy El-Din MM
    Brain Res; 2009 Jan; 1248():96-106. PubMed ID: 19028461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Testing conception of engagement of imidazoline receptors in imidazoline drugs effects on isolated rat heart atria.
    Radwanska A; Dlugokecka J; Wasilewski R; Kaliszan R
    J Physiol Pharmacol; 2009 Mar; 60(1):131-42. PubMed ID: 19439815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of peripheral vascular disease on long-term survival after coronary artery bypass graft surgery.
    Chu D; Bakaeen FG; Wang XL; Dao TK; LeMaire SA; Coselli JS; Huh J
    Ann Thorac Surg; 2008 Oct; 86(4):1175-80. PubMed ID: 18805156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients.
    Vlek AL; van der Graaf Y; Spiering W; Visseren FL;
    J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small artery remodeling in diabetes mellitus.
    Rizzoni D; Rosei EA
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):587-92. PubMed ID: 19481431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Preparation of 2-(benzyl)-imidazoline hydrochloride].
    BINIECKI S; MODRZEJEWSKA W; MUSZYNSKI E
    Acta Pol Pharm; 1955; 12(1):1-4. PubMed ID: 14387778
    [No Abstract]   [Full Text] [Related]  

  • 16. Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension.
    Pretnar-Oblak J; Sebestjen M; Sabovic M
    Am J Hypertens; 2008 Jun; 21(6):674-8. PubMed ID: 18451811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peripheral arterial disease and isolated systolic hypertension: the ATTEST study.
    Safar ME; Priollet P; Luizy F; Mourad JJ; Cacoub P; Levesque H; Benelbaz J; Michon P; Herrmann MA; Blacher J
    J Hum Hypertens; 2009 Mar; 23(3):182-7. PubMed ID: 18830251
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of increased intrahepatic resistance in portal hypertension.
    Shah V
    J Clin Gastroenterol; 2007; 41 Suppl 3():S259-61. PubMed ID: 17975474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension in the very elderly--a call to improve blood pressure management of our PAD patients.
    Wahlberg E
    Eur J Vasc Endovasc Surg; 2008 Oct; 36(4):407-8. PubMed ID: 18675562
    [No Abstract]   [Full Text] [Related]  

  • 20. Pathophysiology of portal hypertension.
    Cichoz-Lach H; Celiński K; Słomka M; Kasztelan-Szczerbińska B
    J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():231-8. PubMed ID: 18812641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.